Zeta FOLR1 Antibody. Zeta’s recombinant rabbit antibody recognizes FOLR1 ((Folate Receptor Alpha), a membrane-bound cysteine-rich cell-surface receptor with high affinity for binding and transporting folate (vitamin B9) into cells. FOLR1 binds to folate and facilitates its internalization into cells through receptor-mediated endocytosis or potocytosis. FOLR1 is important in cellular processes, including DNA synthesis and repair. Overexpression of FOLR1 may confer a growth advantage to tumors by increasing folate uptake and/or may affect cell proliferation via alternative cell signaling pathways. FOLR1 levels have been found to be elevated in tumors of epithelial origin compared to normal tissue, including ovarian, breast, brain, lung and colorectal cancers.
FOLR1 is a tumor marker seen in various epithelial tumors, including high-grade serous ovarian carcinoma (HGSC), endometrial arcinomas (serous subtype), some non–small cell lung cancers (adenocarcinomas), and can help distinguish certain carcinomas from benign or other tumor types, as normal adult tissues generally show restricted expression (e.g., kidney, placenta, some epithelial linings). High expression has been associated with aggressive tumor biology in some cancers, but in others it may correlate with better treatment response if folate-targeted agents are used. The tumor specificity of FOLR1 makes it a promising target for diagnosis and treatment strategies.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.